Germo Gericke, MD
Chief Medical Officer
Germo is an accomplished development expert with a special focus on oncology and radiopharmaceuticals. He joined Ariceum from Advanced Accelerator Applications (AAA), a Novartis company, where he served as Chief Medical Officer and Head of Research and Development building the global R&D organization for Radioligand Therapies. Prior to AAA, Germo led global development programs in oncology and endocrinology. Having joined Novartis in 2001 from McKinsey & Company, he also gained strategic and commercial experience in management roles with increasing responsibility across a range of therapeutic and geographic areas.
Germo studied medicine at Charité University Hospital in Berlin and holds an MD from the University of Heidelberg.